NASDAQ : PROK
ProKidney Corp. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.295 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 391.51M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 287.27M |
| Enterprise Value | 109.23M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 208.93M |
| Shares Outstanding | 302.32M |
| Shares Change (YoY) | +17.54% |
| Shares Change (QoQ) | +31.45% |
| Owned by Insiders (%) | 0.68% |
| Owned by Institutions (%) | 17.71% |
| Float | 184.45M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 478.62 |
| Forward PS | 400.31 |
| PB Ratio | 1.76 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 260.96 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 8.36 |
| Quick Ratio | 8.04 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -9,327.16 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -58.96% |
| Return on Assets (ROA) | -35.66% |
| Return on Invested Capital (ROIC) | -38.85% |
| Return on Capital Employed (ROCE) | -78.31% |
| Weighted Average Cost of Capital (WACC) | 14.01% |
| Revenue Per Employee | $3,541 |
| Profits Per Employee | -$364,325 |
| Employee Count | 231 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -1.03M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.80 |
| 52-Week Price Change | -67.66% |
| 50-Day Moving Average | 1.65 |
| 200-Day Moving Average | 1.81 |
| Relative Strength Index (RSI) | 26.88 |
| Average Volume (20 Days) | 1,302,032 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 24.57M |
| Short Previous Month | 23.79M |
| Short % of Shares Out | 8.13% |
| Short % of Float | 13.32% |
| Short Ratio (days to cover) | 14.72 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 818,000 |
| Gross Profit | 818,000 |
| Operating Income | -177.22M |
| Pretax Income | -166.78M |
| Net Income | -84.16M |
| EBITDA | -170.37M |
| EBIT | -177.22M |
| Loss Per Share | -$0.56 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 181.56M |
| Total Debt | 3.52M |
| Net Cash | 178.04M |
| Net Cash Per Share | $0.59 |
| Equity (Book Value) | 222.84M |
| Book Value Per Share | -4.29 |
| Working Capital | 167.06M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -141.17M |
| Capital Expenditures | -18.57M |
| Depreciation & Amortization | 6.85M |
| Net Borrowing | -8,000 |
| Free Cash Flow | -159.73M |
| FCF Per Share | -$0.53 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -21,664.55% |
| Pretax Margin | -20,388.39% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -17.54% |
| Shareholder Yield | -17.54% |
| Earnings Yield | -58.58% |
| FCF Yield | -40.80% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $6.50 |
| Price Target Difference | 584.07% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | 327.41% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -1.28 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |